{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:26:12Z","timestamp":1771413972495,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Health and Labor Sciences Research Grant","award":["Health and Labor Sciences Research Grant"],"award-info":[{"award-number":["Health and Labor Sciences Research Grant"]}]},{"name":"Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science","award":["Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS)"],"award-info":[{"award-number":["Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS)"]}]},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"crossref","award":["SENSHIN Medical Research Foundation"],"award-info":[{"award-number":["SENSHIN Medical Research Foundation"]}],"id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007716","name":"Banyu Life Science Foundation International","doi-asserted-by":"crossref","award":["Banyu Life Science Foundation International"],"award-info":[{"award-number":["Banyu Life Science Foundation International"]}],"id":[{"id":"10.13039\/100007716","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009666","name":"Salt Science Research Foundation","doi-asserted-by":"crossref","award":["1428"],"award-info":[{"award-number":["1428"]}],"id":[{"id":"10.13039\/100009666","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12944-015-0164-5","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T18:49:28Z","timestamp":1449686968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia"],"prefix":"10.1186","volume":"14","author":[{"given":"Masato","family":"Ohsawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-5372","authenticated-orcid":false,"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Azushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Uneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Haku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Haruhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Kinguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Toya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"164_CR1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303\u20139.","journal-title":"Kidney Int"},{"key":"164_CR2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038\u201347.","journal-title":"JAMA"},{"key":"164_CR3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinte.158.9.998","volume":"158","author":"M Ravid","year":"1998","unstructured":"Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998\u20131004.","journal-title":"Arch Intern Med"},{"key":"164_CR4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","volume":"58","author":"P Muntner","year":"2000","unstructured":"Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293\u2013301.","journal-title":"Kidney Int"},{"key":"164_CR5","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","volume":"14","author":"ES Schaeffner","year":"2003","unstructured":"Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. JASN. 2003;14:2084\u201391.","journal-title":"JASN"},{"key":"164_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","volume":"145","author":"K Douglas","year":"2006","unstructured":"Douglas K, O\u2019Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145:117\u201324.","journal-title":"Ann Intern Med"},{"key":"164_CR7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006\u201316.","journal-title":"J Am Soc Nephrol"},{"key":"164_CR8","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1046\/j.1523-1755.2002.00332.x","volume":"61","author":"C Zoja","year":"2002","unstructured":"Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61:1635\u201345.","journal-title":"Kidney Int"},{"key":"164_CR9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.bcp.2013.04.009","volume":"85","author":"K Wu","year":"2013","unstructured":"Wu K, Tian S, Zhou H, Wu Y. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem Pharmacol. 2013;85:1753\u201360.","journal-title":"Biochem Pharmacol"},{"key":"164_CR10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.metabol.2012.01.006","volume":"61","author":"Y Ishibashi","year":"2012","unstructured":"Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, et al. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism. 2012;61:1067\u201372.","journal-title":"Metabolism"},{"key":"164_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1681\/ASN.V11180","volume":"11","author":"SI Kim","year":"2000","unstructured":"Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol. 2000;11:80\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"164_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10157-012-0676-5","volume":"17","author":"K Ueshima","year":"2013","unstructured":"Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2013;17:211\u20137.","journal-title":"Clin Exp Nephrol"},{"key":"164_CR13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"164_CR14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1751-7176.2012.00640.x","volume":"14","author":"T Kanaoka","year":"2012","unstructured":"Kanaoka T, Tamura K, Ohsawa M, Wakui H, Maeda A, Dejima T, et al. Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients. J Clin Hypertens (Greenwich). 2012;14:522\u20139.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"164_CR15","doi-asserted-by":"crossref","first-page":"437087","DOI":"10.1155\/2014\/437087","volume":"2014","author":"K Azushima","year":"2014","unstructured":"Azushima K, Uneda K, Tamura K, Wakui H, Ohsawa M, Kobayashi R, et al. Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease. Biomed Res Int. 2014;2014:437087.","journal-title":"Biomed Res Int"},{"key":"164_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2015.01.025","volume":"240","author":"K Azushima","year":"2015","unstructured":"Azushima K, Tamura K, Haku S, Wakui H, Kanaoka T, Ohsawa M, et al. Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: a multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2). Atherosclerosis. 2015;240:297\u2013304.","journal-title":"Atherosclerosis"},{"key":"164_CR17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1291\/hypres.25.359","volume":"25","author":"A Yamashina","year":"2002","unstructured":"Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25:359\u201364.","journal-title":"Hypertens Res"},{"key":"164_CR18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","volume":"336","author":"GF Strippoli","year":"2008","unstructured":"Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645\u201351.","journal-title":"BMJ"},{"key":"164_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-157-4-201208210-00005","volume":"157","author":"A Upadhyay","year":"2012","unstructured":"Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:251\u201362.","journal-title":"Ann Intern Med"},{"key":"164_CR20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.atherosclerosis.2009.03.031","volume":"206","author":"H Nakamura","year":"2009","unstructured":"Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206:512\u20137.","journal-title":"Atherosclerosis"},{"key":"164_CR21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","volume":"57","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728\u201334.","journal-title":"J Clin Pathol"},{"key":"164_CR22","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","volume":"111","author":"AA Alsheikh-Ali","year":"2005","unstructured":"Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111:3051\u20137.","journal-title":"Circulation"},{"key":"164_CR23","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/ndt\/gfl244","volume":"21","author":"J Atthobari","year":"2006","unstructured":"Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006;21:3106\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"164_CR24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309\u201311.","journal-title":"Lancet"},{"key":"164_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11906-012-0250-2","volume":"14","author":"L Gyebi","year":"2012","unstructured":"Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep. 2012;14:177\u201381.","journal-title":"Curr Hypertens Rep"},{"key":"164_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jff.2013.12.006","volume":"6","author":"P Scicchitano","year":"2014","unstructured":"Scicchitano P, Cameli M, Maiello M, Modesti P, Muiesan M, Novo S, et al. Nutraceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods. 2014;6:11\u201332.","journal-title":"J Funct Foods"},{"key":"164_CR27","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/01.ASN.0000067413.32377.CF","volume":"14","author":"ME Suliman","year":"2003","unstructured":"Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez Ayala E, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"164_CR28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","volume":"48","author":"E Dounousi","year":"2006","unstructured":"Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48:752\u201360.","journal-title":"Am J Kidney Dis"},{"key":"164_CR29","first-page":"175","volume":"21","author":"S Cottone","year":"2008","unstructured":"Cottone S, Lorito MC, Riccobene R, Nardi E, Mule G, Buscemi S, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008;21:175\u20139.","journal-title":"J Nephrol"},{"key":"164_CR30","doi-asserted-by":"crossref","unstructured":"Kalousova M, Zima T, Tesar V, Sulkova S, Fialova L. Relationship between advanced glycoxidation end products, inflammatory markers\/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int Suppl. 2003;S62\u201364.","DOI":"10.1046\/j.1523-1755.63.s84.19.x"},{"key":"164_CR31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199109193251202","volume":"325","author":"Z Makita","year":"1991","unstructured":"Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836\u201342.","journal-title":"N Engl J Med"},{"key":"164_CR32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s00508-010-1409-y","volume":"122","author":"V Teplan Jr","year":"2010","unstructured":"Teplan Jr V, Vyhnanek F, Gurlich R, Haluzik M, Racek J, Vyhnankova I, et al. Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease. Wien Klin Wochenschr. 2010;122:466\u201373.","journal-title":"Wien Klin Wochenschr"},{"key":"164_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diabetes.48.1.1","volume":"48","author":"JW Baynes","year":"1999","unstructured":"Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1\u20139.","journal-title":"Diabetes"},{"key":"164_CR34","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/meta.2000.7738","volume":"49","author":"T Shimoike","year":"2000","unstructured":"Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism. 2000;49:1030\u20135.","journal-title":"Metabolism"},{"key":"164_CR35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2174\/138161208784139729","volume":"14","author":"S Yamagishi","year":"2008","unstructured":"Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des. 2008;14:962\u20138.","journal-title":"Curr Pharm Des"},{"key":"164_CR36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.nut.2008.12.012","volume":"25","author":"T Roubicek","year":"2009","unstructured":"Roubicek T, Bartlova M, Krajickova J, Haluzikova D, Mraz M, Lacinova Z, et al. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition. 2009;25:762\u20138.","journal-title":"Nutrition"},{"key":"164_CR37","doi-asserted-by":"crossref","unstructured":"Stinghen AE, Massy ZA, Vlassara H, Striker GE, Boullier A. Uremic toxicity of advanced glycation end products in CKD. J Am Soc Nephrol. 2015.","DOI":"10.1681\/ASN.2014101047"},{"key":"164_CR38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM198805193182007","volume":"318","author":"M Brownlee","year":"1988","unstructured":"Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315\u201321.","journal-title":"N Engl J Med"},{"key":"164_CR39","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1073\/pnas.94.12.6474","volume":"94","author":"T Koschinsky","year":"1997","unstructured":"Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"164_CR40","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.2174\/138161207781757051","volume":"13","author":"S Yamagishi","year":"2007","unstructured":"Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des. 2007;13:2832\u20136.","journal-title":"Curr Pharm Des"},{"key":"164_CR41","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1681\/ASN.V781198","volume":"7","author":"T Miyata","year":"1996","unstructured":"Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996;7:1198\u2013206.","journal-title":"J Am Soc Nephrol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-015-0164-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T20:40:16Z","timestamp":1653770416000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.lipidworld.com\/content\/14\/1\/161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1186\/s12944-015-0164-5","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"161"}}